Manufacturers: Bayer
Elinzanetant (Lynkuet) is a non-hormonal neurokinin receptor antagonist manufactured by Bayer, used to treat moderate to severe hot flashes and night sweats. Health Canada authorized it for breast cancer patients after it was first approved in July 2025 to treat these symptoms in women going through menopause; the breast cancer expansion was supported by the Phase 3 OASIS-4 study.
Elinzanetant (Lynkuet) is a non-hormonal neurokinin receptor antagonist manufactured by Bayer, used to treat moderate to severe hot flashes and night sweats. Health Canada authorized it for breast cancer patients after it was first approved in July 2025 to treat these symptoms in women going through menopause; the breast cancer expansion was supported by the Phase 3 OASIS-4 study.
Elinzanetant is a non-hormonal neurokinin receptor antagonist. Neurokinin receptor antagonists target KNDy neurons that can become hyperactive with a lack of estrogen and trigger hot flashes and night sweats; elinzanetant reduces those symptoms by directly targeting those neurons.
Moderate to severe hot flashes and night sweats in breast cancer patients; also approved for vasomotor symptoms in women going through menopause (first approved July 2025). The expansion of the authorization to breast cancer patients was supported by the Phase 3 OASIS-4 study.
3 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
